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BACKGROUND & AIMS: It is not clear whether symptoms
alone can be used to estimate the biologic activity of eosino-
philic esophagitis (EoE). We aimed to evaluate whether symp-
toms can be used to identify patients with endoscopic and
histologic features of remission. METHODS: Between April
2011 and June 2014, we performed a prospective, observa-
tional study and recruited 269 consecutive adults with EoE
(67% male; median age, 39 years old) in Switzerland and the
United States. Patients first completed the validated symptom-
based EoE activity index patient-reported outcome instrument
and then underwent esophagogastroduodenoscopy with
esophageal biopsy collection. Endoscopic and histologic find-
ings were evaluated with a validated grading system and
standardized instrument, respectively. Clinical remission was
defined as symptom score <20 (range, 0100); histologic
remission was defined as a peak count of <20 eosinophils/
mm2 in a high-power field (corresponds to approximately <5eosinophils/median high-power field); and endoscopic
remission as absence of white exudates, moderate or severe
rings, strictures, or combination of furrows and edema. We
used receiver operating characteristic analysis to determine
the best symptom score cutoff values for detection of remis-
sion. RESULTS: Of the study subjects, 111 were in clinical
remission (41.3%), 79 were in endoscopic remission (29.7%),
and 75 were in histologic remission (27.9%). When the
symptom score was used as a continuous variable, patients in
endoscopic, histologic, and combined (endoscopic and histo-
logic remission) remission were detected with area under the
curve values of 0.67, 0.60, and 0.67, respectively. A symptom
score of 20 identified patients in endoscopic remission with
65.1% accuracy and histologic remission with 62.1% accu-
racy; a symptom score of 15 identified patients with both
types of remission with 67.7% accuracy. CONCLUSIONS: In
patients with EoE, endoscopic or histologic remission can be
identified with only modest accuracy based on symptoms
alone. At any given time, physicians cannot rely on lack of
symptoms to make assumptions about lack of biologic disease
activity in adults with EoE. ClinicalTrials.gov, Number:
NCT00939263.
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antigen-mediated, esophageal disease characterized clini-
cally by symptoms related to esophageal dysfunction and
histologically by eosinophil-predominant inflammation.”1,2
Dysphagia is the leading EoE symptom in adult patients,
but swallowing-associated pain and heartburn not
responding to acid-suppressive medication can also occur.1,2
In Europe and the United States, a steady increase in EoE
incidence and/or prevalence has been observed during the
past 2 decades with a current prevalence of about 1/2,000
inhabitants.3–10
Despite the urgent need for EoE-specific therapies, to
date, no such therapy has been approved by regulatory
agencies, including the US Food and Drug Administration
and the European Medicines Agency. There are 2 major
hurdles in the way of seeking regulatory approval for EoE-
specific therapies: first, standardized and validated in-
struments for reliable assessment of disease activity have
been lacking for a long time and, second, there is an ongoing
debate among different stakeholders regarding the choice of
clinically relevant end points for use in clinical trials and
natural history studies.11,12
Recently, considerable progress has been made toward
developing and validating instruments for standardized
disease activity assessment. Among others, the EoE endo-
scopic reference score, developed by Hirano et al, for
grading the severity of distinct EoE-associated endoscopic
features (edema, rings, exudates, furrows, and strictures)
and the eosinophilic esophagitis activity index (EEsAI)
patient-reported outcome (PRO) instrument for assessing
clinical activity in adult patients, are now available for use in
various studies.13,14
A dissociation between EoE symptom severity and his-
tologic activity was documented in some, but not other
studies.15–18 This leaves clinicians with uncertainty as to the
elements upon which their therapeutic decisions should be
based. Specifically, it is currently unknown whether physi-
cians can rely solely on EoE-related symptoms when esti-
mating the severity of endoscopic and histologic activity in a
given patient.
The purpose of this study was to examine the relation-
ship between clinical activity and biologic activity (endos-
copy, histology) of EoE. Specifically, we aimed to examine
the ability of the EEsAI PRO score to detect endoscopic and
histologic remission in adult EoE patients. We also aimed to
examine whether the previous EoE-specific treatment im-
pacts the relationship between clinical and biologic EoE
activity, and, in so doing, alters the ability of the EEsAI PRO
score to detect biologic remission. This study may help to
elucidate whether treatment decisions can be based solely
on symptoms, or whether the biologic findings obtained
during more invasive procedures, such as esophagogas-
troduodenoscopy (EGD) with biopsy sampling, should also
be taken into consideration.Methods
Study Population
The study was registered on ClinicalTrials.gov
(NCT00939263) and approved by local institutional review
boards and ethics committees. All authors had access to the study
data and reviewed and approved the final manuscript.
Adult EoE patients (17 years of age) were consecutively
recruited in 1 ambulatory care clinic and 5 hospitals in
Switzerland and the United States between April 2011 and June
2014. All patients were treated by 6 gastroenterologists (AMS,
JA, ED, NG, IH, and AS) specializing in EoE (each gastroenterol-
ogist has treated >50 EoE patients and performed >1000
EGDs). Patients provided written informed consent for partici-
pation in the study. All patients in need of an EGD for initial
diagnosis, for confirming a suspected diagnosis, or for moni-
toring previously diagnosed EoE were invited to participate in
the study. Patients were diagnosed by investigators according to
standardized criteria.1,2 EoE patients with concomitant gastro-
esophageal reflux disease were also included, provided that they
fulfilled the following criteria: they were on continued proton-
pump inhibitor therapy at the time of EGD; they had no symp-
toms of gastroesophageal reflux disease; and they had no evi-
dence of acute reflux-related lesions. Before undergoing EGD,
patients completed the EEsAI PRO instrument (in paper form).14
Assessment of Symptoms and Behavioral
Adaptations to Living With Dysphagia
Development and validation of the EEsAI PRO instrument
has been described recently.14 The EEsAI PRO instrument was
developed in accordance with the US Food and Drug Admin-
istration guidelines.19,20 The instrument queries the following
symptoms and behavioral adaptations to living with dysphagia
recalled during a 7-day period: frequency of trouble swallow-
ing, duration of trouble swallowing, thoracic pain when swal-
lowing, trouble swallowing caused by foods of different
consistencies, and behavioral adaptations to living with
dysphagia, including avoidance; modification; and slow
eating.14 The EEsAI PRO score ranges from 0 to 100 points.
Assessment of Eosinophilic
EsophagitisAssociated Endoscopic and
Histologic Findings
During EGD, at least 4 biopsies from the proximal and 4 bi-
opsies from the distal esophagus were obtained. For this study,
we defined “distal” esophagus as the section of the esophagus 5
cm above the gastroesophageal junction and “proximal” esoph-
agus as the section spanning the top half of the esophagus.
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such as edema, rings, exudates, furrows, and stricture(s) in the
proximal and distal esophagus, was carried out by the treating
physician in accordance with the EoE Endoscopic Reference
Score classification and grading system.13 For the purposes of
this study, white exudates, furrows, and edema were considered
to represent endoscopic features associated with acute inflam-
mation, and fixed rings and strictures were considered to
represent features associated with chronic inflammation.13,21
Histologic evaluation of esophageal biopsies was performed
by the local center pathologist with expertise in EoE. Five-
micrometer sections were cut from paraffin blocks and then
stained with H&E for examination by light microscopy. At least
5 levels of every esophageal biopsy specimen were surveyed,
and the eosinophils in the most densely infiltrated area were
counted under high-power examination (magnification 400).
The following features were recorded: size of high-power field
(hpf [in mm2]), quality of sample orientation, percentage of the
hpf covered by the tissue, peak number of eosinophils/hpf,
distribution of eosinophils in an hpf, distribution of inflamma-
tion, presence of abscesses, basal layer enlargement, and lam-
ina propria fibrosis.
Definitions of Endoscopic and Histologic
Remission
We used the following definitions of endoscopic remission:
Endoscopic inflammatory remission
 absence of white exudates
 furrows and edema may be present, but not in combination
Endoscopic fibrotic remission
 absence of moderate and severe rings
 absence of strictures
Total endoscopic remission (inflammatory and fibrotic
remission):
 absence of white exudates
 furrows and edema may be present but not in combination
 absence of moderate and severe rings
 absence of strictures
We used the following definitions of histologic remission:
peak count of <20 eosinophils/mm2 of hpf and peak count of
<60 eosinophils/mm2 of hpf. The data on peak eosinophil
counts are presented as per mm2.22 The rationale for the
definitions of histologic remission was as follows: median hpf
size was 0.26 mm2 (interquartile range, 0.260.307 mm2; range,
0.2040.545 mm2). Therefore, <20 eosinophils/mm2 and <60
eosinophils/mm2 correspond to approximately <5 eosinophils/
median hpf and <15 eosinophils/median hpf, respectively.
We defined “deep remission” as the combination of endo-
scopic inflammatory and fibrotic remission, as well as histologic
remission (peak eosinophil count <20/mm2 of hpf).
Data Handling and Statistical Analysis
The investigators at various centers sent the completed
instruments to the data center at the Institute of Social andPreventive Medicine (University of Bern, Switzerland). Two
researchers (ES, NH) double-entered the data into an EpiData
database (version 3.1, EpiData Association, Odense, Denmark).
The original records were checked to resolve any discrepancies.
The study dataset was imported into Stata (version 13, Stata-
Corp, College Station, TX) for analysis.
Descriptive results are presented as frequencies and cor-
responding percentages of the group total or median and
interquartile range. To obtain the severity of the EoE-associated
endoscopic and histologic findings for the esophagus overall,
the most severe category for a given finding identified in
proximal and distal esophagus was chosen. If data on severity
of a given finding in one part of the esophagus were missing,
then severity of that finding for another part of the esophagus
was chosen as the one representing severity of that finding for
the esophagus overall.
We performed several analyses in order to evaluate the
accuracy of distinct EEsAI PRO values to detect endoscopic or
histologic remission. First, we calculated the sensitivity, speci-
ficity, positive predictive value, negative predictive value, and
diagnostic accuracy of distinct EEsAI PRO score values to detect
endoscopic and histologic remission at all possible EEsAI PRO
values. The diagnostic accuracy is expressed as a proportion of
the correctly classified subjects (true positive and true negative)
among all subjects (true and false positive as well as true and
false negative). Second, to determine the optimal cutoff value of
the EEsAI PRO score for detecting endoscopic or histologic
remission, we constructed receiver operating characteristics
(ROC) curves. The ROC curve is a plot of the true-positive rate
(sensitivity) vs the false-positive rate (1  specificity) for the
different possible cutoff values of a diagnostic test. The closer
the curve follows the left-hand border and the top border of the
ROC space, the more accurate the diagnostic test is.23 Therefore,
the optimal cutoff value is the highest PRO score, which sits
closest (Euclidean distance) to the top-left corner of the ROC
space. The area under the ROC curve (AUC) was calculated from
fitting logistic regression models (for each remission type) with
the EEsAI PRO score as a continuous variable. A perfect test for
discrimination between individuals with and without a given
outcome has an AUC of 1.0, and a test that discriminates be-
tween these individuals with and without this outcome no
better than chance has an AUC of 0.50. To examine whether the
association between the EEsAI PRO score and the remission
depends is modified by previous treatments (esophageal dila-
tion, hypoallergenic diet, or swallowed topical corticosteroids),
interaction tests between the EEsAI PRO score and different
treatments were performed. The ROC curve analysis was
repeated for treatment subgroups, if the interaction test with
the EEsAI PRO score proved significant (P < .05).
Results
Patient Characteristics
A total of 269 adult patients with previously diag-
nosed EoE according to the established criteria were pro-
spectively included into the study.1 Patient characteristics
are shown in Table 1. One hundred and fifty-nine patients
(59.1%) had EoE symptom onset of >5 years before being
recruited into the study. At the time of the study, asthma,
rhinoconjunctivitis, eczema, and food allergies were self-
reported by 97 patients (36.1%), 163 patients (60.6%), 52
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Gastroesophageal reflux disease was diagnosed in 64
patients (23.8%). In the last 12 months before their
participation in this study, 141 patients (52.4%), 37 patients
(13.8%), and 53 patients (19.7%) had been treated for EoE
with swallowed topical corticosteroids, hypoallergenic diets,
and esophageal dilation, respectively.
Eosinophilic EsophagitisAssociated
Endoscopic and Histologic Features
The EoE-associated endoscopic and histologic findings in
proximal and distal esophagus, as well as for “esophagusTable 1.Patient Characteristics, Comorbidities, and
Treatments
Characteristics
Patients, N 269
Males 180 (66.9)
Age at inclusion, median (IQR), range, y 39.2 (3047), 1880
EEsAI PRO score, median (IQR), range 27 (1242), 094
Ethnicity
White 259 (96.3)
Non-white 10 (3.7)
Education
Compulsory schooling 4 (1.5)
Vocational training 69 (25.7)
Upper secondary education 119 (44.2)
University education 77 (28.6)
EoE symptoms onset
<1 mo ago to 11 mo ago 12 (4.5)
1 to 5 y ago 98 (36.4)
>5 y ago 159 (59.1)
Atopic diseases/allergiesa ever in life 206 (76.6)
Asthma 97 (36.1)
Rhinoconjunctivitis 163 (60.6)
Eczema 52 (19.3)
Food allergy 113 (42.0)
Gastroesophageal reflux disease 64 (23.8)
Clinically 3 (4.7)
Endoscopically 6 (9.4)
Based on pH-metric studies 2 (3.1)
Clinically and endoscopically 5 (7.8)
Concomitant medications in the past 7 d
Proton-pump inhibitors 121 (45.0)
Histamine antagonists (H2-receptor) 7 (2.6)
Histamine antagonists (H1-receptor) 42 (15.6)
Inhaled corticosteroids for asthma 8 (3.0)
b2-adrenergic agonists for asthma 23 (8.6)
Leukotriene receptor antagonists for
asthma
5 (1.9)
EoE-specific treatments in the last 12 mo 190 (70.6)
Hypoallergenic diets in last 90 d 37 (13.8)
Swallowed topical corticosteroids in last
90 d
141 (52.4)
Esophageal dilation in last 12 mo 53 (19.7)
NOTE. Values are n (%) unless otherwise noted.
IQR, interquartile range.
aPatients self-reported lifetime (ever in life) atopies by
answering the following item: “Have you ever been told by a
doctor or another health professional that you had asthma/
allergy-related nose problem/eczema/food allergy?”overall,” are shown in Supplementary Table 1. Endoscopic
findings were graded in accordance with the EoE endo-
scopic reference score.13 The frequency of distinct endo-
scopic findings was similar when the proximal esophagus
was compared with the distal esophagus. If esophagus
overall was examined, the following frequencies of endo-
scopic features were observed: exudates in 91 patients
(33.8%), rings in 195 patients (72.5%), edema in 155
patients (57.6%), and strictures in 90 patients (33.5%).
The prevalence of distinct histologic findings was similar
when the distal esophagus was compared with the proximal
esophagus. Median peak eosinophil count was 92 per mm2
of hpf (interquartile range, 14260; range, 01293 peak
eosinophils/mm2). Eosinophilic abscesses were observed in
53 patients (19.7%).
Relationship Between Clinical, Endoscopic,
and Histologic Activity
The proportion of patients with distinct EEsAI PRO
scores, as well as endoscopic inflammatory, endoscopic
fibrotic, total endoscopic, histologic, and deep remission at
the time of inclusion in the study is shown in Table 2.
Test accuracy of distinct EEsAI PRO score cutoff values
to detect endoscopic inflammatory, endoscopic fibrotic, and
total endoscopic remission is shown in Table 3. Results of
the ROC curve analysis are shown in Figure 1 for endoscopic
inflammatory remission (Figure 1A), endoscopic fibrotic
remission (Figure 1B), and total endoscopic remission
(Figure 1C). The AUC was 0.6719 for detection of total
endoscopic remission when compared with 0.6680 and
0.6238 for detection of endoscopic fibrotic and endoscopic
inflammatory remission, respectively. A PRO score of 20
identified patients in endoscopic inflammatory remission
with 62.1% accuracy and in total endoscopic remission with
65.1% accuracy; a score of 30 identified patients in endo-
scopic fibrotic remission with 62.1% accuracy.
We evaluated the test accuracy of distinct EEsAI PRO
score cutoff values to detect histologic remission. These
results are shown in Table 4. The results of ROC curve
analysis are shown in Figure 1D and E. The AUC was 0.6007
and 0.6060 for detecting histologic remission defined as
peak eosinophil count of <20/mm2 and <60/mm2 of hpf,
respectively. A PRO score of 20 points identified patients in
histologic remission of <20 eosinophils/mm2 of hpf with
overall accuracy of 62.1% and in histologic remission of
<60 eosinophils/mm2 of hpf with 61.7% accuracy.
Lastly, we examined the diagnostic accuracy of distinct
EEsAI PRO score cutoff values to detect deep remission
(Table 5). The corresponding ROC curve with EEsAI PRO
score as continuous variable for detection of deep remission
is shown in Figure 1F. The AUC was 0.6719. An EEsAI PRO
score of 15 points had an overall accuracy of 67.7% to
detect patients in deep remission.
Impact of Treatment on the Relationships Among
Clinical, Endoscopic, and Histologic Activity
We found that interaction terms between EEsAI PRO
score and previous EoE-specific treatments were not
Table 2.Proportion of Patients in Clinical (Using 3 Different EEsAI PRO Score Cutoff Values), Endoscopic, and Histologic
Remission
n %
Patients with certain symptom score OR in endoscopic OR histologic remission
EEsAI PRO score <30 points 162 60.2
EEsAI PRO score <25 points 112 41.6
EEsAI PRO score <20 points 111 41.3
Endoscopic inflammatory remission 117 43.5
Endoscopic fibrotic remission 148 55.0
Total endoscopic remission 79 29.4
Histologic remission (peak count of <20 eosinophils/mm2) 75 27.9
Patients with certain symptom score AND in endoscopic remission
EEsAI PRO score <30 AND in endoscopic inflammatory remission 85/162 52.5
EEsAI PRO score <30 AND in endoscopic fibrotic remission 104/162 64.2
EEsAI PRO score <30 AND in total endoscopic remission 63/162 38.9
EEsAI PRO score <25 AND in endoscopic inflammatory remission 63/112 56.3
EEsAI PRO score <25 AND in endoscopic fibrotic remission 75/112 67.0
EEsAI PRO score <25 AND in total endoscopic remission 48/112 42.9
EEsAI PRO score <20 AND in endoscopic inflammatory remission 63/111 56.8
EEsAI PRO score <20 AND in endoscopic fibrotic remission 75/111 67.6
EEsAI PRO score <20 AND in total endoscopic remission 48/111 43.2
Patients with certain symptom score AND in histologic remission
EEsAI PRO score <30 AND in histologic remission (<20 eosinophils/mm2) 51/162 31.5
EEsAI PRO score <25 AND in histologic remission (<20 eosinophils/mm2) 42/112 37.5
EEsAI PRO score <20 AND in histologic remission (<20 eosinophils/mm2) 42/111 37.8
Patients with certain symptom score AND in endoscopic AND histologic remission
EEsAI PRO score <30 AND in total endoscopic AND histologic remission 32/162 19.8
EEsAI PRO score <25 AND in total endoscopic AND histologic remission 25/112 22.3
EEsAI PRO score <20 AND in total endoscopic AND histologic remission 25/111 22.5
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swallowed topical corticosteroids. However, a statistically
significant interaction term (P ¼ .0412) suggested that the
relationship between EEsAI PRO score and total endoscopic
remission changes, depending on whether a patient was
treated with a dilation in the 12 months before inclusion.
Therefore, we evaluated whether dilation influences the
relationships among clinical, endoscopic, and histologic ac-
tivity by first examining the frequency of the EoE-associated
endoscopic and histologic findings in proximal and distal
esophagus, as well as for esophagus overall (shown in
Supplementary Table 2) in the patient group that under-
went dilation in the last 12 months before inclusion in the
study (n ¼ 53) and in the patient group that did not un-
dergo dilation (n ¼ 213; dilation status of 3 patients was
unknown). Patients that underwent dilation in the last 12
months before inclusion into the study were more likely to
have strictures, moderate and severe rings, as well as white
exudates and eosinophilic microabscesses when compared
with patients that did not undergo dilation. The results of
ROC curve analysis in patients stratified into groups based
on absence or presence of dilation are shown in
Supplementary Table 3. In the group of patients that un-
derwent dilation, we found a good diagnostic accuracy for
the EEsAI PRO instrument to detect patients in endoscopic
fibrotic remission (AUC 0.768, optimal PRO value 25 points)
and in deep remission (defined as endoscopic fibrotic and
inflammatory as well as histologic remission) (AUC 0.863,optimal PRO value 25 points) (Supplementary Figure 1). In
the nondilated patients, the AUC for all types of remission
were similar to those observed when the entire study
population was examined together.Discussion
In this study, we examined the relationship between
symptoms as measured by EEsAI PRO score and biologic
findings in adults with EoE. We found that endoscopic and/
or histologic remission can be identified with only modest
accuracy based on symptoms alone. Therefore, at any given
time, physicians cannot rely on lack of symptoms to make
assumptions about lack of biologic disease activity in adult
EoE patients.
Accurate detection of endoscopic or histologic remission
by the means of a symptom-based instrument would reduce
the need to perform regular endoscopic and histologic
follow-up examinations. This, in turn, would considerably
reduce the burden of disease for patients and EGD-
associated health care costs. We found that the overall ac-
curacy of detecting endoscopic and histologic remission
based on distinct EEsAI PRO score cutoff values was modest
(AUC ranging between 0.6 and 0.7). At present, data on the
accuracy of other EoE-specific symptom-based activity in-
struments to detect endoscopic and histologic remission are
lacking. When comparing the accuracy of the EEsAI PRO
instrument to clinically based instruments used in other
Table 3.Accuracy of Patient-Reported Clinical Symptoms (Assessed Using EEsAI PRO Score) to Detect Endoscopic
Remission
EEsAI PRO score cutoff
Cumulative
remissions,a
n (%)
Cumulative
frequency,b
n (%)
PPV,
%
NPV,
%
Sensitivity,
%
Specificity,
%
Accuracy,
%
Endoscopic inflammatory
remission
15 55/96 (57.3) 96/269 (35.7) 57.3 64.2 47.0 73.0 61.7
20 63/111 (56.8) 111/269 (41.3) 56.8 65.8 53.8 68.4 62.1
25 63/112 (56.3) 112/269 (41.6) 56.3 65.6 53.8 67.8 61.7
30 85/162 (52.5) 162/269 (60.2) 52.5 70.1 72.6 49.3 59.5
35 87/180 (48.3) 180/269 (66.9) 48.3 66.3 74.4 38.8 54.3
Endoscopic fibrotic
remission
15 66/96 (68.8) 96/269 (35.7) 68.8 52.6 44.6 75.2 58.4
20 75/111 (67.6) 111/269 (41.3) 67.6 53.8 50.7 70.2 59.5
25 75/112 (67.0) 112/269 (41.6) 67.0 53.5 50.7 69.4 59.1
30 104/162 (64.2) 162/269 (60.2) 64.2 58.9 70.3 52.1 62.1
35 114/180 (63.3) 180/269 (66.9) 63.3 61.8 77.0 45.5 62.8
Total endoscopic
remission (inflammatory
and fibrotic)
15 43/96 (44.8) 96/269 (35.7) 44.8 79.2 54.4 72.1 66.9
20 48/111 (43.2) 111/269 (41.3) 43.2 80.4 60.8 66.8 65.1
25 48/112 (42.9) 112/269 (41.6) 42.9 80.3 60.8 66.3 64.7
30 63/162 (38.9) 162/269 (60.2) 38.9 85.0 79.7 47.9 57.2
35 63/180 (35.0) 180/269 (66.9) 35.0 82.0 79.7 38.4 50.6
NOTE. Data for 5 different cutoff values of EEsAI PRO score are shown.
NPV, negative predictive value; PPV, positive predictive value.
aNumber of patients in endoscopic remission for a given EEsAI PRO score cutoff value.
bNumber of patients with a given EEsAI PRO score below the cutoff value.
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PRO score (using a score of 20 points as a cutoff) was better
at detecting endoscopic remission (accuracy 65%) in EoE
patients when compared with detection of endoscopic
remission by means of the Crohn’s Disease Activity Index
(CDAI).24 Specifically, a CDAI score <100 points had an
overall accuracy of 55% in detecting endoscopic remission,
and a CDAI score of <150 points had an overall accuracy of
56% in detecting endoscopic remission.24 As of yet, no data
on the accuracy of various clinical scores to detect histologic
remission in Crohn’s disease patients have been published.
This is related, in part, to the fact that no formally accepted
definition of histologic remission exists for both EoE and
Crohn’s disease. Given that the size of an hpf varied, we
standardized the peak eosinophil count per mm2. We chose
a cutoff value of <20 eosinophils/hpf to define histologic
remission, which corresponds to a value of <5 eosinophils/
hpf for a median hpf size of 0.26 mm2. An EEsAI PRO score
of 20 points had an overall accuracy of 62% to detect his-
tologic remission.
Why is the test accuracy of detecting biologic remission
based on the adult EEsAI PRO score only modest (AUC
0.60.7)? First, we found in a previous study that the
perception of mild and moderate endoscopic or histologic
alterations in adult EoE patients seems to be relatively
poor.14 Only patients with severe endoscopic features had
relevant symptoms.14 We made similar observations whenwe analyzed the relationship between patient quality of life
(as assessed by an adult EoE quality of life instrument) and
endoscopic and histologic alterations.25,26 Patients with
mild or moderate endoscopic and histologic features had
relatively good quality of life (low adult EoE quality of life
instrument score). However, the quality of life score was
considerably poorer in patients with severe endoscopic in-
flammatory and/or fibrotic alterations or histologic inflam-
mation (eg, presence of microabscesses).25 These results
together suggest that endoscopically and histologically mild
disease does not cause any symptoms or else very mild
symptoms to which patients become accustomed over time.
These findings are corroborated by a long diagnostic delay
observed in EoE patients.21 Second, symptoms in EoE pa-
tients are mainly generated by altered esophageal motility
caused by the presence of eosinophil-predominant inflam-
mation and/or subepithelial fibrous tissue deposition
(esophageal remodeling) that decreases the esophageal
compliance.27,28 Sampling 4 proximal and 4 distal esopha-
geal biopsies has a very good accuracy (>95%) for detecting
the degree of mucosal eosinophilic inflammation.29 How-
ever, consistently sampling subepithelial esophageal tissue
with standard biopsy forceps might be quite difficult. Only
61% of all patients included into our study had subepithelial
tissue that could be evaluated for presence of fibrosis. As
such, our knowledge of processes occurring deeper in the
esophageal wall and contributing to subtle stricture
Figure 1. Receiver operator curve analysis was carried out to determine the best EEsAI PRO score cutoff value to detect
endoscopic inflammatory remission (A), endoscopic fibrotic remission (B), endoscopic inflammatory and fibrotic remission (C),
histologic remission defined as peak eosinophil count of <20/mm2 (D), histologic remission defined as peak eosinophil count
of <60/mm2 (E), and deep remission defined as the combination of endoscopic inflammatory and fibrotic remission as well as
histologic remission (peak eosinophil count of <20/mm2) (F). eos, eosinophils; OPT, optimal.
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words, using biopsy sampling alone, we underestimate the
degree of esophageal remodeling processes and inflamma-
tion that could potentially contribute to symptom genera-
tion. Indeed, upon histologic examination of specimens
obtained from patients that underwent esophagectomy, an
extensive lamina propria fibrosis contributing to increased
wall thickness was observed.30,31 In addition, eosinophilic
infiltration was observed not only in the mucosa, but
throughout the esophageal wall as well, this infiltration
penetrated the submucosa.30,31 In the future, technologies
such as the Endolumenal Functional Lumen Imaging Probe,
which allows assessment of esophageal diameter and
esophageal compliance, will help physicians to better esti-
mate the extent of esophageal remodeling and overall EoE
activity beyond the endoscopic and histologic alterations.32
Given that untreated subclinical eosinophilic inflammation
can lead to stricture formation (which represents the main
risk factor for the food bolus impactions), we conclude that
physicians should not only rely on patient-reported symp-
toms, but also on endoscopic and histologic findings when
assessing disease severity in studies or during the clinical
follow-up of adult EoE patients.21When we examined the effect of different EoE-specific
therapies on the relationship between EEsAI PRO score
and various types of remission, we found that this rela-
tionship was not affected by treatment with hypoallergenic
diets and swallowed topical corticosteroids in the 3 months
before inclusion into the study. However, the relationship
between EEsAI PRO score and the total endoscopic remis-
sion changes, depending on whether patients underwent
dilation in the 12 months before inclusion or not. In the
attempt to explain this phenomenon, we examined the fre-
quency of various endoscopic fibrotic and inflammatory
findings, such as mild and severe exudates, moderate
and severe rings, as well as strictures in dilated and non-
dilated patients. We found that patients that underwent
dilation were actually more likely to have these findings
when compared with patients that did not undergo
dilation. As previously discussed, patients seem to perceive
more extreme endoscopic findings. Therefore, over-
representation of extreme findings in the group of patients
that underwent dilation is the reason behind a good diag-
nostic accuracy of the EEsAI PRO score for detection of
endoscopic fibrotic remission (and by extension total
endoscopic remission and deep remission). However, this
Table 4.Accuracy of Patient-Reported Clinical Symptoms (Assessed Using EEsAI PRO Score) to Detect Histologic Remission
EEsAI PRO score cutoff
Cumulative
remission,a
n (%)
Cumulative
frequency,b
n (%)
PPV,
%
NPV,
%
Sensitivity,
%
Specificity,
%
Accuracy,
%
Histologic remission: peak count of
<20 eosinophils/mm2
15 38/96 (39.6) 96/269 (35.7) 39.6 78.6 50.7 70.1 64.7
20 42/111 (37.8) 111/269 (41.3) 37.8 79.1 56.0 64.4 62.1
25 42/112 (37.5) 112/269 (41.6) 37.5 79.0 56.0 63.9 61.7
30 51/162 (31.5) 162/269 (60.2) 31.5 77.6 68.0 42.8 49.8
35 54/180 (30.0) 180/269 (66.9) 30.0 76.4 72.0 35.1 45.4
Histologic remission: peak count of
<60 eosinophils/mm2
15 49/96 (51.0) 96/269 (35.7) 51.0 70.5 49.0 72.2 63.6
20 54/111 (48.6) 111/269 (41.3) 48.6 70.9 54.0 66.3 61.7
25 54/112 (48.2) 112/269 (41.6) 48.2 70.7 54.0 65.7 61.3
30 68/162 (42.0) 162/269 (60.2) 42.0 70.1 68.0 44.4 53.2
35 71/180 (39.4) 180/269 (66.9) 39.4 67.4 71.0 35.5 48.7
NOTE. Data for 5 different cutoff values of EEsAI PRO score are shown.
NPV, negative predictive value; PPV, positive predictive value.
aNumber of patients in histologic remission for a given EEsAI PRO score cutoff value.
bNumber of patients with a given EEsAI PRO score below the cutoff value.
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ATraises another important issue relating to the kind of effect
that various EoE-specific treatments have on underlying
disease biology and symptoms. Although treatment with
hypoallergenic diets and swallowed topical corticosteroids
impacts the underlying disease biology and, in so doing,
leads to symptom improvement, treatment with dilation
does not change underlying disease biology.33 However,
dilation can lead to long-lasting improvement in symptoms.
This disconnect between disease biology and symptoms
might be another reason behind the perturbed relationship
between EEsAI PRO score and remission in patients that
underwent dilation.
Our study has strengths and some limitations as well.
We evaluated the relationship between symptom severity
on the one hand, and endoscopic and histologic activityTable 5.Accuracy of Patient-Reported Clinical Symptoms (Ass
EEsAI PRO score cutoff
Cumulative
remission,b
n (%)
Cum
frequ
n
Deep remission (total endoscopic
and histologic remission)
15 25/96 (26.0) 96/26
20 26/111 (23.4) 111/26
25 26/112 (23.2) 112/26
30 33/162 (20.4) 162/26
35 33/180 (18.3) 180/26
NOTE. Data for 5 different cutoff values of EEsAI PRO score ar
NPV, negative predictive value; PPV, positive predictive value.
aDefined as endoscopic inflammatory and fibrotic remission i
eosinophil count <20/mm2).
bNumber of patients in deep remission for a given EEsAI PRO
cNumber of patients with a given EEsAI PRO score below the con the other, using validated instruments for assessment
of clinical and endoscopic activity in a well-defined, pro-
spectively enrolled EoE population. However, the findings of
our study should be interpreted with a number of consid-
erations in mind. First, we did not evaluate the relationship
between clinical activity and various novel tests, such as
blood biomarkers (eg, blood eosinophil levels or serum
levels of eosinophilic cationic protein), the esophageal string
test, cytosponge, or the Endolumenal Functional Lumen
Imaging Probe.32,3436 Some of these might further enhance
our ability to estimate EoE activity. Second, the EEsAI PRO
instrument was designed specifically for use in adult pa-
tients; we do not know whether similar observations would
also hold true in a pediatric population, where symptoms
related to inflammation rather than fibrosis predominate.essed Using EEsAI PRO Score) to Detect Deep Remissiona
ulative
ency,c
(%)
PPV,
%
NPV,
%
Sensitivity,
%
Specificity,
%
Accuracy,
%
9 (35.7) 26.0 90.8 61.0 68.9 67.7
9 (41.3) 23.4 90.5 63.4 62.7 62.8
9 (41.6) 23.2 90.4 63.4 62.3 62.5
9 (60.2) 20.4 92.5 80.5 43.4 49.1
9 (66.9) 18.3 91.0 80.5 35.5 42.4
e shown.
n combination with histologic remission (defined as a peak
score cutoff value.
utoff value.
March 2016 Detecting Biologic Remission Using Symptoms 589In summary, given the imperfect concordance between
patient-reported symptoms and endoscopic/histologic
findings, physicians cannot rely on lack of symptoms to
make assumptions about lack of biologic disease activity in
adult EoE patients.L
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Supplementary Figure 1. Receiver operator curve analysis was carried out to determine the best EEsAI PRO score cutoff
value to detect endoscopic fibrotic remission (A) and deep remission (B) in EoE patients that underwent esophageal dilation in
the last 12 months before inclusion. The EEsAI PRO score of 25 points had an overall accuracy of 77.4% to detect patients in
endoscopic fibrotic remission. The EEsAI PRO score of 25 points had an overall accuracy of 71.7% to detect patients in deep
remission. Deep remission defined as combined endoscopic fibrotic and inflammatory remission as well as histologic
remission (cutoff value of <20 eosinophils/mm2). OPT, optimal.
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Supplementary Table 1.Endoscopic and Histologic Findings in Proximal and Distal Esophagusa
Characteristic
Proximal Distal Overall
n % n % n %
Endoscopic findings
Fixed rings
Absent 105 39.0 81 30.1 74 27.5
Mild 89 33.1 100 37.2 100 37.2
Moderate 59 21.9 74 27.5 78 29.0
Severe 13 4.8 13 4.8 17 6.3
Missing 3 1.1 1 0.4 0 0
Strictures
Absent 221 82.2 194 72.1 179 66.5
Present 42 15.6 74 27.5 90 33.5
Missing 6 2.2 1 0.4 0 0
Exudates
Absent 205 76.2 184 68.4 178 66.2
Mild 49 18.2 69 25.7 75 27.9
Severe 14 5.2 14 5.2 16 5.9
Missing 1 0.4 12 0.7 0 0
Furrows
Absent 137 50.9 105 39.0 102 37.9
Present 131 48.7 163 60.6 167 62.1
Missing 1 0.4 1 0.4 0 0
Edema
Absent 141 52.4 115 42.7 114 42.4
Present 127 47.2 153 56.9 155 57.6
Missing 1 0.4 1 0.4 0 0
Histologic findings
Peak eosinophil count/mm2
016 107 39.8 80 29.7 73 27.1
1764 35 13.0 40 14.9 37 13.8
65320 78 29.0 110 40.9 108 40.1
>320 32 11.9 38 14.1 51 19.0
Missing 17 6.3 1 0.4 0 0
Abscesses
Absent 226 84.0 225 83.6 216 80.3
Present 38 14.1 42 15.6 53 19.7
Missing 5 1.9 2 0.7 0 0
Basal layer enlargement
<14% 101 37.5 82 30.5 79 29.4
1433% 93 34.6 94 34.9 96 35.7
3466% 50 18.6 62 23.0 66 24.5
>67% 14 5.2 23 8.6 25 9.3
Cannot be evaluated 7 2.6 7 2.6 3 1.1
Missing 4 1.5 1 0.4 0 0
Lamina propria
Absent 131 48.7 108 40.1 96 35.7
Present, can be evaluated 128 47.6 152 56.5 164 61.0
Present, cannot be evaluated 6 2.2 8 3.0 9 3.3
Missing 4 1.5 1 0.4 0 0
Lamina propria fibrosisb
Absent 16 12.5 9 5.9 11 6.7
Mild/moderate 78 60.9 115 75.2 110 66.7
Severe 34 26.6 29 19.0 44 26.7
aThese findings were also summarized for esophagus overall.
bSeverity of fibrosis is given for those patients, in whose biopsies lamina propria was present and could be evaluated (n ¼ 128
for proximal esophagus; n ¼ 152 for distal esophagus; n ¼ 164 for esophagus overall).
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Supplementary Table 2.Endoscopic and Histologic Findings
in Patients That Underwent Dilation
in the 12 Months Before Enrollment
and in Those That Did Not
Characteristic
Dilation No dilation
n % n %
Endoscopic findings
Fixed rings
Absent 10 18.9 63 29.6
Mild 14 26.4 86 40.4
Moderate 24 45.3 53 24.9
Severe 5 9.4 11 5.2
Strictures
Absent 25 47.2 153 71.8
Present 28 52.8 60 28.2
Exudates
Absent 32 60.4 144 67.6
Mild 16 30.2 59 27.7
Severe 5 9.4 10 4.7
Furrows
Absent 21 39.6 81 38.0
Present 32 60.4 132 62.0
Edema
Absent 23 43.4 90 42.3
Present 30 56.6 123 57.7
Histologic findings
Peak eosinophils count/mm2
016 14 26.4 57 26.8
1764 6 11.3 31 14.6
65320 22 41.5 85 39.9
>320 11 20.8 40 18.8
Abscesses
Absent 34 64.2 179 84.0
Present 19 35.8 34 16.0
Basal layer enlargement
<14% 23 43.4 55 25.8
1433% 15 28.3 80 37.6
3466% 10 18.9 55 25.8
>67% 4 7.5 21 9.9
Cannot be evaluated 1 1.9 2 0.9
Lamina propria
Absent 17 32.1 76 35.7
Present, can be evaluated 34 64.2 130 61.0
Present, cannot be evaluated 2 3.8 7 3.3
Lamina propria fibrosisa
Absent 5 14.7 6 4.6
Mild/moderate 19 55.9 91 69.5
Severe 10 29.4 34 26.0
aSeverity of fibrosis is given for those patients in whose
biopsies lamina propria was present and could be evaluated.
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Supplementary Table 3.Test Characteristics of the EEsAI PRO Score in Detecting Endoscopic and/or Histologic Remission in
Patients That Either Underwent Esophageal Dilation in the Last 12 Months Before Inclusion or Did
Not
Outcomes
Dilation (n ¼ 53) No dilation (n ¼ 213)
AUC
Optimal PRO
value
Sensitivity,
specificity,
accuracy, % AUC
Optimal PRO
value
Sensitivity,
specificity,
accuracy, %
Endoscopic inflammatory
remission
0.603 30 58.3, 72.4, 66.0 0.631 21 55.4, 65.3, 61.0
Endoscopic fibrotic remission 0.768 25 68.8, 81.1, 77.4 0.631 21 48.9, 64.6, 54.9
Total endoscopic remission
(inflammatory and fibrotic)
0.814 27 83.3, 80.5, 81.1 0.638 19 56.7, 65.8, 62.9
Histologic remission (cut-off value
<20 eosinophils/mm2)
0.524 30 46.2, 60, 56.6 0.630 19 60.0, 66.0, 64.3
Histologic remission (cut-off value
<60 eosinophils/mm2)
0.522 30 52.6, 64.7, 60.4 0.627 19 57.0, 67.9, 63.8
Deep (total endoscopic and
histologic) remissiona
0.863 25 100, 70, 71.7 0.646 15 60.5, 64.6, 63.8
aDeep remission was defined as endoscopic inflammatory and fibrotic remission as well as histologic remission (cutoff value of
<20 eosinophils/mm2 of hpf).
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